New Jetrea Formulation Eliminates Dilution Step

Jetrea is indicated for the treatment of symptomatic vitreomacular adhesion
Jetrea is indicated for the treatment of symptomatic vitreomacular adhesion

ThromboGenics announced that the Food and Drug Administration (FDA) has approved a new "already-diluted" formulation of Jetrea (ocriplasmin) intravitreal injection.

Jetrea, a proteolytic enzyme, is indicated for the treatment of symptomatic vitreomacular adhesion. Ocriplasmin has proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (eg, laminin, fibronectin and collagen), thereby dissolving the protein matrix responsible for the vitreomacular adhesion. 

Related Articles

The new formulation removes the preparatory steps for dilution prior to injection. Its strength, potency, composition, and pharmaceutical form is identical to the currently available formulation of Jetrea after dilution. 

The already-diluted formulation of Jetrea is anticipated to launch in the first half of 2017. It is currently supplied as a 2.5mg/mL strength solution for intravitreal injection in single-use 0.2mL vials.

For more information call (855) 253-7396 or visit Jetrea.com.

Loading links....